Pedro Hermida de Viveiros, MD
Hematology & Oncology · Chicago, ILNPI 1427512847
Payments from drug & device makers
Across 253 payments — averaging $2782.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$555K
- Springworks Therapeutics, Inc.$97K
- Servier Bioinnovation$39K
- Deciphera Pharmaceuticals Inc.$5K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- EMD Serono, Inc.$3K
- plus $970 from 13 others
Across 2 payments — averaging $219.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$440
What the payments were for
- Consulting fees$12,50012%
- Speaking & faculty fees$76,13472%
- Travel & lodging$12,81912%
- Food & beverage$4,7434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $554,619 |
| Springworks Therapeutics, Inc. | 188 | $97,350 |
| Servier Bioinnovation | 18 | $39,435 |
| Deciphera Pharmaceuticals Inc. | 9 | $5,026 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $3,780 |
| EMD Serono, Inc. | 1 | $2,850 |
| Daiichi Sankyo Inc. | 2 | $254 |
| Aadi Bioscience, Inc. | 2 | $205 |
| Foundation Medicine, Inc. | 1 | $130 |
| Johnson & Johnson | 5 | $127 |
| Exelixis Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Merck | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OGSIVEO$92,357
- QINLOCK$2,340
- VIMSELTINIB$1,755
- ROMVIMZA$585
- FOUNDATIONONE LIQUID CDX$130
- Turalio$128
- VANFLYTa$126
- FYARRO$105
How this compares
$704,029 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 26 | $41,747 |
| Dexamethasone | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chicago
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
- Wendy StockChicago$7.2M
- Justin KlineChicago$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.